Intellia Therapeutics Inc (NTLA) support and resistance · rev $57.9M
Intellia Therapeutics Inc (NTLA) is a biotechnology company listed on US.
This page maps Intellia Therapeutics Inc (NTLA) support and resistance from cached range and valuation — not a live tape and not a trade alert.
Latest reported NTLA revenue for 2024-12-31 was $57.9M. Net income was -$519.0M. Revenue was up 59.6% from 2023-12-31 to 2024-12-31. NTLA currently screens at market cap $1.19B.
NTLA currently screens at market cap $1.19B. Round numbers near that cap and multiple often act as psychological resistance; prior-period revenue is the fundamental floor traders argue about.
A new NTLA 8-K or 10-Q can move the levels that matter more than a drawing on a chart.
Not investment advice. Use the NTLA quote page for the session range and the stock page for the full model.
Not investment advice.